Hepatitis B – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Hepatitis B Market Outlook
Thelansis’s “Hepatitis B Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Hepatitis B treatment modalities options
for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and
China).
Hepatitis
B Overview
Hepatitis
B is primarily transmitted via contact with infected blood or certain bodily
fluids. Common transmission routes include perinatal transfer from an infected
mother to her newborn during childbirth, unsterile medical or dental equipment,
unprotected sex, unsterile needles, and sharing personal items such as razors,
toothbrushes, and nail clippers. Hepatitis B is often termed a “silent
epidemic” as most individuals are asymptomatic during acute or chronic
infection, leading to unintentional viral transmission and ongoing propagation
of the virus. Chronic asymptomatic carriers may still experience progressive
liver damage, potentially resulting in cirrhosis or liver cancer. The hepatitis
B virus (HBV) has a complex replication cycle, entering host liver cells and
transforming its DNA into covalently closed circular DNA (cccDNA) within the
nucleus. This cccDNA serves as a template for viral replication. Newly formed
HBV particles are released from the liver cell while cccDNA persists in the
nucleus, where it can integrate into the host genome and continue viral
production. The replication process is prone to errors, contributing to the
genetic diversity of HBV.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment